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Manufacturing techniquesAbstract Over the past few decades, tendency toward innovative drug delivery systems has
majorly increased attempts to ensure efﬁcacy, safety and patient acceptability. As discovery and
development of new chemical agents is a complex, expensive and time consuming process, so recent
trends are shifting toward designing and developing innovative drug delivery systems for existing
drugs. Out of those, drug delivery system being very eminent among pediatrics and geriatrics is
orally disintegrating ﬁlms (ODFs). These fast disintegrating ﬁlms have superiority over fast disinte-
grating tablets as the latter are associated with the risks of choking and friability. This drug delivery
system has numerous advantages over conventional fast disintegrating tablets as they can be used
for dysphasic and schizophrenic patients and are taken without water due to their ability to disinte-
grate within a few seconds releasing medication in mouth. Various approaches are employed for
formulating ODFs and among which solvent casting and spraying methods are frequently used.
Generally, hydrophilic polymers along with other excipients are used for preparing ODFs which
allow ﬁlms to disintegrate quickly releasing incorporated active pharmaceutical ingredient (API)
within seconds. Orally disintegrating ﬁlms have potential for business and market exploitation
because of their myriad of beneﬁts over orally disintegrating tablets. This present review attempts
to focus on beneﬁts, composition, approaches for formulation and evaluation of ODFs.
Additionally, the market prospect of this innovative dosage form is also targeted.
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Oral route of drug administration is a most preferred route due
to its ease of administration, non-invasiveness, adaptability,
patient compliance and acceptability. Regarding oral route
of drug administration, many substitutes have continuously
been presented by using recent novel technologies for pedia-
trics, geriatrics, nauseous and non-compliance patients.
Bioadhesive mucosal dosage forms including adhesive tablets,
gels and patches are outcomes of technological development.
Among various dosage forms, the use of polymeric ﬁlms for
delivering medication into buccal cavity has developed great
potential in recent era (Arya et al., 2010). Orally disintegrating
ﬁlms (ODFs), when placed on tongue, immediately hydrates
by soaking saliva following disintegration and/or dissolutionreleasing active pharmaceutical agent from the dosage form
(Chauhan et al., 2012). ODFs are kind of formulations which
are commonly prepared using hydrophilic polymers enabling
rapid dissolution upon contact with saliva. Oral disintegrating
tablets (ODTs) and oral disintegrating ﬁlms (ODFs) are the
typical examples of orally disintegrating drug delivery systems.
These systems were developed in late 1970 to serve as an alter-
native to conventional dosage forms, for instance, fast disinte-
grating tablets and capsules for geriatrics and pediatric
patients having difﬁculty in swallowing conventional dosage
forms (Liew et al., 2012). A typical ODF is usually equal to
the size of a postage stamp. In market place, the introduction
of ODT was strongly associated with counseling of patients
about the appropriate administration by giving instruction like
‘‘do not chew/do not swallow’’. However, in spite of these
Table 2 Ideal properties of hydrophilic polymers.
Properties
Non-irritant
Should not hinder with the disintegration time of ODF
Aﬀordable
Should possess adequate shelf-life
Should possess good spread ability
Should exhibit suﬃcient tensile strength
Should have good mechanical properties
Non-toxic
Non-irritant
Orally disintegrating ﬁlms 539instructions, incidents regarding chewing and swallowing were
often reported. But, ODFs untied the masses from these
adverse events. The administration of ODFs has numerous
advantages and some of them are as follows:
i. Easy transportation.
ii. Ease of swallowing for geriatrics and pediatrics.
iii. Convenient and accurate dosing.
iv. No need of water for administration.
v. Convenient for dysphasic patients having difﬁculty in
swallowing tablets and capsules.
vi. Rapid onset of action with increased bioavailability due
to bypassing hepatic ﬁrst pass effect and stability
(Choudhary et al., 2012).
No expensive lyophilization, high mechanical strength,
rapid disintegration, and reduced choking risks are the quality
attributes of ODFs (Arya et al., 2010; Preis et al., 2012; Goel
et al., 2008). ODFs have attained remarkable signiﬁcance in
pharmaceutical industry for the reason of possessing unique
properties and fast disintegration time ranging from seconds
to one minute (Choudhary et al., 2012). ODFs design permits
to incorporate a variety of drugs for their pharmacological
effects e.g., anti-tussive, anti-epileptic, anti-asthmatic, expec-
torant, etc. (Arya et al., 2010). High temperature and moisture
sensitivity necessitating expensive packaging and inability of
high dose loading are some disadvantages of ODFs.
2. Formulation
ODFs are fast disintegrating thin ﬁlms having an area ranging
from 5 to 20 cm2 in which drug is incorporated in the form of
matrix using hydrophilic polymer. Active pharmaceutical
ingredient can be incorporated up to 15 mg along with other
excipients i.e., plasticizers, colorants, sweeteners, taste masking
agents, etc. Plasticizer increases workability, spreadability and
ﬂexibility of ﬁlms thereby reducing the glass transition tem-
perature of polymers. The general composition of an ODF is
shown in Table 1 (Arya et al., 2010).
2.1. Active pharmaceutical ingredient
Various classes of drugs can be incorporated into ODFs e.g.,
anti-histamine, anti-diarrheal, anti-depressants, vasodilators,
anti-asthmatic, anti-emetic, etc. (Chauhan et al., 2012).
Dimenhydrinate can also be incorporated into ODFs for taste
masking. Common examples of drugs incorporated into ODFs
are salbutamol sulfate, rizatriptan benzoate, verapamil,
ondansetron, dexamethasone, rofecoxib, cetirizine, pilocar-
pine, tianeptine sodium, indomethacin, etc. (Preis et al.,
2012). An ODF of anti-emetic agent like prochlorperazineTable 1 Composition of a typical ODF.
Components Conc. (%)
Active pharmaceutical ingredient 1–25
Hydrophilic polymer 40–50
Plasticizer 0–20
Color, ﬁller, ﬂavor 0–40was also formulated by employing microcrystalline cellulose
and other ﬁlm forming polymers (Nishimura et al., 2009).
2.2. Hydrophilic polymers
The successful development of an ODF is a function of justi-
ﬁed selection and concentration of polymers as the mechanical
strength of ﬁlms is strongly associated with these factors. They
can be used either alone or in combination with other polymers
to modify ﬁlm properties. The concentration of used polymers
is also important factor while developing an ODF. The integ-
rity of fast dissolving oral ﬁlms is dependent upon careful
selection of polymer nature and concentration. Generally,
polymer concentration used in preparing ODFs is around
45% w/w of total weight of dry thin strip, however, it can be
increased up to 60–65% w/w in order to attain the ﬁlm of
desired attributes and characteristics. Polymer used as a ﬁlm
forming agent in formulation of thin strips should possess cer-
tain properties (Table 2).
In recent era, both natural and artiﬁcial polymers are used
for developing ODF formulation (Table 3) (Chauhan et al.,
2012).
Different polymers are employed to modulate diverse prop-
erties of ﬁlms. Pullulan has increased solubility next to the
property of enhancing ﬂexibility and ﬁlms incorporating pull-
ulan have high tensile strength and stability over a wide range
of temperature. Molecular weights of gelatins affect the prop-
erties of prepared ﬁlms and a signiﬁcantly appealing ﬁlm can
be attained by using polymers with higher average molecular
weight. The combination of chitosan and high methoxy pectin
(HMP) or low methoxy pectin (LMP) provides excellent qual-
ity of strip. Cellulose derived ﬁlm forming polymers viz
hydroxypropyl methylcellulose (HPMC), hydroxypropyl cellu-
lose (HPC), methyl cellulose (MC) and carboxymethyl cellu-
lose (CMC) give ﬁlms with less water vapor barrier due to
their hydrophilic nature. Polyethylene glycol (PEG) also hasTable 3 Most commonly used natural and synthetic polymers
in ODFs.
Type of
polymer
Examples
Natural Starch, polymerized rosin, pullulan, sodium
alginate, Pectin, gelatin, and maltodextrins
Synthetic Polyvinyl alcohol, hydroxy propyl methyl cellulose,
sodium carboxy methyl cellulose, polyvinyl
pyrrolidone, and hydroxy propyl cellulose
Table 4 Examples of some commonly used sweetening agents
in ODFs.
Sweetening
agent
Example
Natural Glucose, fructose, dextrose, sucrose, and
isomaltose
Artiﬁcial Acesulfame-K, sucralose, and neotame
540 M. Irfan et al.a good ﬁlm forming properties either alone or in combination
with other polymers (Pathare et al., 2013).
HPMC is a very good ﬁlm former and different grades viz
Methocel E3, Methocel E5, Methocel E15 Premium LV, etc.
are available. The development of fast dissolving ﬁlm of tri-
closan prepared by using different grades of HPMC indicated
that Methocel E15 Premium LV resulted into the ﬁlms with
appropriate properties (Dinge and Nagarsenker, 2008). Fast
dissolving ﬁlm of famotidine fabricated using HPMC and
polyethylene glycol (PEG) depicted desired physico-chemical
properties (Sonawane et al., 2012). A water insoluble drug
(piroxicam) was incorporated into fast dissolving ﬁlms pre-
pared using maltodextrins (MDX) and equivalent low dose
dextrose (Cilurzo et al., 2008). ODFs of nebivolol HCl pre-
pared from HPMC, pullulan, polyvinyl pyrrolidone (PVP)
illustrated that changing polymers concentration profoundly
affects mechanical properties and percentage drug release
(Parejiya et al., 2012). As polymers govern the release proﬁle,
mono- and double-layered buccoadhesive ﬁlms of chlorhexi-
dine were prepared to portray this fact. Films prepared with
alginate and/or HPMC and/or chitosan controlled drug release
in a better way (Juliano et al., 2008). ODFs of granisetron
hydrochloride manufactured using pullulan and HPMC
illustrated the effect of polymer concentration on mechanical
properties and strength of ﬁlm. Pullulan with 40–45% concen-
tration did not yield ﬁlms with good properties whereas
HPMC up to 40% amount resulted into ﬁlms which were
difﬁcult to peel. Furthermore, the stickiness of ﬁlm increased
when the concentration of HPMC was above 50%
(Chaudhary et al., 2013). A study of preparing fast dissolving
ﬁlms of losartan potassium applying different concentrations
of maltodextrin (MD) and polyvinyl alcohol (PVA) demon-
strated that in vitro disintegration time varied directly as a
function of increased polymer concentration (Bansal et al.,
2013). Another study revealed that pullulan serves as a best
ﬁlm forming agent among all investigated polymers
(Kulkarni et al., 2010). Fast dissolving ﬁlms of cetirizine using
2% w/v pullulan were thin and brittle, thus, slightly higher
concentration was used (Mishra and Amin, 2011). Affectivity
of ODFs might be judged by comparing the pharmacokinetic
properties (blood proﬁle) of the reference (oral solution of pure
drug) and the sample ﬁlm of levocetirizine containing pullulan
by testing on Sprague–Dawley rats (Choudhary et al., 2012).
2.3. Plasticizers
In general, mechanical properties such as tensile strength and
percent elongation are improved by adding plasticizer to the
formulations (Arya et al., 2010). The concentration of plastici-
zer usually ranges from 0% to 20% w/w. Common examples
of plasticizers are PEG, glycerol, diethyl phthalate, triethyl
citrate, tributyl citrate, etc. (Bala et al., 2013).
2.4. Surfactants
Surfactants play a vital role as dispersing, wetting and sol-
ubilizing agent thus enabling ﬁlms to disintegrate within sec-
onds releasing the incorporated drug, speedily. Commonly
used surfactants are benzalkonium chloride, tweens, and
sodium lauryl sulfate. Often, polaxamer 407 is used due to
its many advantages (Siddiqui et al., 2011).2.5. Flavor
Flavors are needed to mask the bitter or nauseating taste of
incorporated drug. Amount of ﬂavor depends upon its nature
and strength. Any US-FDA approved ﬂavor can be used such
as sweet, sour or mint ﬂavor (Siddiqui et al., 2011). One of the
research work veriﬁed that mint, licorice and sucralose mixture
ﬂavors appropriately mask the bitter taste of diclofenac
sodium. Electronic tongues are used to discriminate the effect
of various taste masking agents (TMAs) (Cilurzo et al., 2011).
2.6. Sweetening agents
Sweetening agents are designed to disintegrate or dissolve in
oral cavity. Both artiﬁcial and natural sweeteners are used in
preparing ODFs (Table 4).
Neotame and Alitame are 2000–8000 times sweeter than
sucrose (Siddiqui et al., 2011). Fructose has more sweetening
power compared to sorbitol and mannitol (Desu et al.,
2013). Sucralose was found to be 600–1000 times sweeter than
sucrose when oral disintegrating ﬁlms of donepezil were evalu-
ated for taste, after taste mouth feel. Aspartame and saccharin
sodium are likely to be 200 and 300–500 times sweeter com-
pared to sucrose, respectively. It was also reported that sweet-
eners and ﬂavors have minor effect on ﬂexibility of ﬁlm (Liew
et al., 2012).
2.7. Saliva stimulating agent
Salivary stimulants are generally acidic in nature stimulating
the production of saliva in buccal cavity, consequently, pro-
moting the disintegrating of ODFs. Some commonly used sal-
iva stimulating agents are citric acid, malic acid, tartaric acid,
ascorbic acid and lactic acid (Siddiqui et al., 2011).
2.8. Coloring agents
Pigments are used as coloring agents. Titanium dioxide is most
widely used colorant in ODFs and various other pharmaceuti-
cal preparations. Apart from titanium dioxide, a full range of
colors are available including FD and C, natural and custom
pantone-matched colors (Siddiqui et al., 2011).
3. Conventional approaches for manufacturing of orodispersible
ﬁlms
Methods mainly employed for manufacturing ODFs are
shown in Fig. 1 (Siddiqui et al., 2011).
Figure 1 Conventional approaches for manufacturing ODFs.
Orally disintegrating ﬁlms 5413.1. Solvent casting method
Solvent casting is the most commonly used method for the pre-
paration of ODFs using water soluble excipients, polymers and
drug which are dissolved in de-ionized water; consequently, a
homogenous mixture is obtained by applying high shear forces
generated by a shear processor. Then, the prepared solution is
poured onto petri plate and the solvent is allowed to dry by
exposing it to high temperature in order to attain good quality
ﬁlms (Fig. 2) (Choudhary et al., 2012; Thakur et al., 2012).
An orodispersible ﬁlm of tianeptine sodium was success-
fully prepared through solvent casting technique using differ-
ent grades of Lycoat and HPMC (El-Setouhy and El-Malak,
2010). In solvent casting technique, ﬁlm forming polymer isMixing of drug,
polymer and
excipients
Homogenization 
by magnetic 
stirrer
Figure 2 Flow chart of s
Figure 3 Description of sousually soaked in an appropriate solvent for overnight. The
type of API, which has to be incorporated in ODF, governs
the selection of a suitable solvent depending on critical phy-
sico-chemical properties of API such as melting point, shear
sensitivity and polymorphic form. Compatibility of drug with
solvent and other excipients is also brought under considera-
tion before ﬁnalizing a formulation. During formulation,
entrapment of air bubbles can hinder the uniformity of pre-
pared ﬁlms. Thus, deaeration of the mixture is carried out with
the help of a vacuum pump (Fig. 3) (Panda et al., 2012).
Orodispersible ﬁlm formulation of mosapride was also suc-
cessfully prepared by using solvent casting method (ElMeshad
and Hagrasy, 2011). Viscosity of the solution to be poured is
an imperative aspect in casting method. The concentration of
pullulan varying from 2% to 8% results into low viscosity
solution, as a result, enabling easy casting of ﬁlms (Murata
et al., 2010). Fast disintegrating ﬁlms of anastrozole were also
effectively prepared with the help of solvent casting method
employing HPMC (E5) and polyvinyl alcohol (PVA)
(Satyanarayana and Keshavarao, 2012).
3.2. Semi-solid casting method
Flow map of semi-solid casting method is given below in Fig. 4
(Thakur et al., 2012).
3.3. Hot melt extrusion
Hot melt extrusion is a technique in which a mixture contain-
ing drug, polymer and excipients is extruded under highSetting aside for 8 
h
Casting on Petri
plate
Drying in hot
air oven (45-50°C)
Peeling and 
cutting
olvent casting method.
lvent casting technique.
Mixing of 
hydrophilic acid 
insoluble 
Addition of 
plasticizer to form 
a gelled mass
Rolling Drying and 
cutting 
Figure 4 Flow map of semi-solid casting method.
542 M. Irfan et al.temperature to form a homogenous mass which is then casted
to form smooth ﬁlms. This is a solvent free process, however,
the processing of thermolabile substances is a major drawback
of this process due to the use of high temperature during extru-
sion (Fig. 5) (Thakur et al., 2012; Panda et al., 2012).
3.4. Solid dispersion extrusion
Solid dispersion of domperidone using beta-cyclodextrin, PEG
400 and HPMC E15 was successfully prepared and ﬁlms were
casted using solid dispersion extrusion method (Fig. 6)
(Thakur et al., 2012; Joshi et al., 2012).
3.5. Rolling method
Plot of rolling method is shown in Fig. 7 (Thakur et al., 2012).
The prepared solution should possess speciﬁc rheological
properties for rolling onto the drum (Panda et al., 2012).Mixing of
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Addition of drug 
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Spraying of solution of polymer, drug and other 
excipients over a suitable carrier support
Figure 8 Manufacturing of3.6. Spray technique
Drug substance, polymers and all other excipients are dis-
solved in a suitable solvent to form a clear solution. This clear
solution is then sprayed onto suitable material such as glass,
polyethylene ﬁlm of non-siliconized Kraft paper or Teﬂon
sheet (Fig. 8) (Panda et al., 2012).
4. Characterization and evaluation
Characterization of ﬁlms is accomplished via following tests:
4.1. Organoleptic evaluation
Special controlled human taste panels are used for such pur-
pose. This in vivo taste evaluation is carried out on human
volunteers. In-vitro taste evaluation of ODFs is performed
by using taste sensors for screening. In vitro taste assessingExtrusion Drying and 
cutting 
t melt extrusion method.
polymer along
ponents
Cutting of solid 
dispersion into film
lid dispersion method.
Evaporation of 
solvent 
Cutting of 
film
rolling method.
Material is dried and peeled off from 
support to get film of desired size
ODFs by spray method.
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high-throughput taste sensing of such dosage forms. Both
in vivo and in vitro techniques analyze the taste masking abil-
ity and sweetness level of taste masking agents.
4.2. Mechanical properties
4.2.1. Thickness test
Thickness of a ﬁlm is determined by using calibrated digital
micrometer and then subsequently mean average is calculated.
Generally, three readings from all the batches are determined
and average is calculated. Weight variation of a ﬁlm is calcu-
lated in triplicate by cutting the ﬁlm and determining weight
of each ﬁlm. Uniformity in thickness is important to ascertain
as it is directly proportional to dose accuracy of the ﬁlm.
4.2.2. Dryness test/tack test
This test is performed to ﬁnd out the ability of a ﬁlm to get
adhered to a piece of paper pressed between strips
(Chaudhary et al., 2013). Obstinacy with which the ﬁlm
adheres with the piece of paper or any other accessory pressed
in between the ﬁlms is known as tack. Almost there are eight
stages of ﬁlm drying process which are identiﬁed viz dry-to
touch, dry-to-recoat, dry hard, set-to-touch, dust-free, dry-
through, tack-free and dry print-free. Primarily these tests
are used to evaluate dryness of ﬁlms in paint industry but
are also adoptable for assessing orally fast disintegrating ﬁlms.
Dryness or tack test can also be performed by with the help of
some newly invented instruments (Bhyan et al., 2011).
4.2.3. Tensile strength
Tensile strength is deﬁned as maximum stress applied at which
the ﬁlm breaks. Basically, this test is performed to measure the
mechanical strength of ﬁlms. It can be calculated from applied
load at rupture divided by the strip cross-sectional area given
in the equation below:
Tensile strength ¼ ðload at failure=strip thickness
 strip widthÞ  1004.2.4. Percent elongation
Upon exerting stress on a ﬁlm, the specimen stretches which is
referred as strain. Strain is deﬁned as change in length of ﬁlm
divided by its original/initial length of the ﬁlm specimen.
Percent elongation is related quantitatively to the amount of
plasticizer used in ﬁlm formulation. Increased plasticizer con-
centration in the ﬁlm generally results in enhanced elongation
of the strip. It is determined by the following formula:
Percentage elongation ¼ ðchange in length=initial lengthÞ
 1004.2.5. Tear resistance
Tear resistance of ﬁlm is the intricate function of its ultimate
resistance to rupture. Maximum force required to tear the ﬁlm
is measured as tear resistance value. This test is typically attrib-
uted to plastic industry. The rate of loading employed is 2 in/
min which is planned to determine the magnitude of force
required to initiate tearing in the ﬁlm specimen. The maximumamount of force necessary for tearing is generally found near
the tearing onset which is ranked as tear resistance value
(Bhyan et al., 2011).
4.2.6. Young’s modulus
It is the measure of ﬁlm stiffness. It is found as ratio of applied
stress to the strain in the elastic deformation region. It is deter-
mined by the following formula:
Young’s modulus ¼ ðslope=strip thickness
 cross head speedÞ  100
It can also be written as:
Young’s modulus ¼ force at corresponding
strain=cross-sectional area
 corresponding strain
Hardness and brittleness are characteristics of the ﬁlms
which are related with Young’s modulus and tensile strength.
A hard and brittle ﬁlm depicts higher value of tensile strength
and Young’s modulus with small elongation (Bhyan et al.,
2011).
4.2.7. Folding endurance
Folding endurance is another procedure to estimate the
mechanical properties of a ﬁlm. It is measured by repeatedly
folding a ﬁlm at the same point until it breaks. Folding endur-
ance value is number of times the ﬁlm is folded without break-
ing. Higher folding endurance value depicts the more
mechanical strength of a ﬁlm. A direct relation exists between
mechanical strength and folding endurance of ﬁlms. As
mechanical strength is governed by plasticizer concentration
so it is clearly evident that plasticizer concentration also indi-
rectly affects folding endurance value.
4.3. Swelling property
Simulated saliva solution is used to check the swelling studies
of ﬁlms. Initial weight of ﬁlm is determined and is placed in
pre-weighed stainless steel wire mesh. This mesh containing
ﬁlm is then dipped into simulated saliva solution. Increase in
the weight of ﬁlm is noted at constant pre-determined time
intervals until no more increase in weight. Degree of swelling
is determined by these parameters:
Degree of swelling ¼ final weight ðwtÞ
 initial weight ðw0Þ=initial weight ðw0Þ
wt =weight of ﬁlm at time interval t; w0 = weight of ﬁlm at
time 0.
4.4. Transparency
Transparency of a strip is determined by using a UV-spec-
trophotometer. This test is performed for visual appearance
of the formulation. Film specimen are cut into rectangular
shapes and placed on the internal side of the photometer cell.
Transmittance of the ﬁlm is worked out at 600 nm wavelength.
Formula for determining transparency is given as:
Transparency ¼ ðlog T600Þ=b ¼ €c
544 M. Irfan et al.T600 = transmittance at 600 nm, b= ﬁlm thickness (mm),
and c= concentration.
4.5. Contact angle
Contact angle of a ﬁlm is usually measured at room tempera-
ture with the help of a device known as goniometer. On the dry
ﬁlm surface, a drop of double distilled water is placed. Water
droplet images are recorded within 10 s after the placement
of drop with the help of a digital camera. These digital pictures
are analyzed by using image 1.28 V software for determining
contact angle. Contact angle is measured on both sides of dro-
plets and mean is calculated. Contact angle is determined at
least ﬁve times at different positions to have a clear idea about
the nature of ﬁlms.
4.6. Content uniformity
Contents of a ﬁlm are determined by standard assay method
speciﬁed for individual drug in different pharmacopoeia.
This test is performed on 20 samples using analytical tech-
niques. The acceptance value of the test is less than 15% in
accordance with Japanese pharmacopoeia. According to
USP27, the contents should range from 85% to 115% with
the standard deviation of less than or equal to 6%
(Chaudhary et al., 2013). Content uniformity is worked out
for estimating drug contents in individual ﬁlm (Bhyan et al.,
2011).
4.7. Disintegration time
Disintegration apparatus mentioned in ofﬁcial pharmaco-
poeias is used for determining the disintegration time of a
ﬁlm. Normally, the disintegration time is the function of
composition of ﬁlm as it varies with the formulation and
generally ranges from 5 to 30 s. Mostly, the USP disinte-
gration apparatus is used for this test. There are no ofﬁcial
guidelines available for determining disintegration time of
orally fast disintegrating ﬁlms (Bhyan et al., 2011). There
are two methods for determining disintegration time of
ﬁlm:
4.7.1. Slide frame method
A drop of distilled water is poured onto the ﬁlm clamped into
slide frames placed on petri dish. Time taken by the ﬁlm to dis-
solve is noted.
4.7.2. Petri dish method
A ﬁlm is placed onto 2 ml distilled water taken in petri dish.
Time taken by the ﬁlm to dissolve completely is considered
as the disintegrating time (Patil et al., 2014).
4.8. In-vitro dissolution test
Standard ofﬁcial basket or paddle apparatus is used for con-
ducting dissolution studies on ﬁlms. Sink conditions should
be maintained during dissolution. Sometimes while perform-
ing this process, ﬁlm ﬂoats over the medium making it difﬁ-
cult to perform the test properly. This problem is more likely
to occur in case of paddle method thus the basket apparatusis mostly preferred. Media used are 6.8 pH phosphate buffer
(300 ml) and 0.1 N HCl (900 ml). Temperature is maintained
at 37 ± 0.5 C and rotation speed of 50 rpm is usually
adjusted. Samples of drug dissolved are collected at pre-deter-
mined intervals and are analyzed by using UV-spectropho-
tometer. Despite its extensive use, dissolution test is still
prone to noteworthy inaccuracy and tests letdown (Bai
et al., 2007).
4.9. Visual inspection and surface morphology
Visual inspection of a prepared orodispersible ﬁlm gives infor-
mation about color, homogeneity and transparency (Raju
et al., 2011). For surface morphology, scanning electron micro-
scopy is performed. Absence of pores and surface uniformity
depicts good quality of ﬁlms.
4.10. Surface pH
The pH value of a ﬁlm is usually determined by putting the
prepared ﬁlm in petri dish and subsequently ﬁlm is made wet
by using distilled water and noting pH by touching the ﬁlm
surface with a pH meter electrode. Determination of surface
pH is vital as acidic or basic pH is liable to cause oral mucosal
irritation (Patel and Poddar, 2009).
4.11. Moisture uptake and moisture loss
Percent moisture loss is a parameter that determines the
hygroscopicity of a ﬁlm. Usually, this parameter is deter-
mined by ﬁrst ﬁnding the initial weight of the ﬁlm, after-
ward, putting this ﬁlm in a dessicator for three days.
Dessicator contains calcium carbonate. After three days,
strips are taken out and weighed again. Moisture loss is
determined by applying the following formula (Yellanki
et al., 2011).
Percentage moisture loss ¼ initial weight
 final weight=initial weight
 100
Moisture uptake of a ﬁlm is determined by ﬁrst cutting the
ﬁlm with the dimension of 2 · 2 cm2. Afterward these strips
are exposed to environment with a relative humidity of
75% at room temperature for 7 days. Moisture uptake is
determined as percent weight gain of the strips (Gorle and
Gattani, 2009).
Percentage moisture uptake ¼ final weight
 initial weight=initial weight
 1005. Packaging of orally disintegrating ﬁlms
Packing considerations are critical for storage, protection and
stability of dosage form. Packaging for oral thin ﬁlms includes
foil paper or plastic pouches, single pouch, aluminum pouch,
blister packaging with multiple units and barrier ﬁlms.
Barrier ﬁlms are most commonly used for those drugs which
Orally disintegrating ﬁlms 545are extremely moisture sensitive (Patil et al., 2014). Rapid ﬁlm
technology developed by Labtec GmbH describes primary
packaging made of a sealing pouch affords enough space for
logos, codes, instructions or other information. The ﬁlms are
manufactured by a laminating process and packaging costs
are comparable to tablets (Bhasin et al., 2011).
6. Conclusion
The present review shows that oral fast disintegrating ﬁlms are
one of the novel approaches in the ﬁeld of pharmaceutical
sciences. They have improved acceptance and patient compli-
ance with no risk of choking associated with better safety
and efﬁcacy in comparison with conventional dosage forms.
The main idea behind formulation of ODFs was to cope with
the difﬁculty in swallowing conventional oral dosage forms
among pediatric, geriatric and psychiatric patients with dys-
phagia. Presently, ODFs are widely available for hypertension,
acidity, allergy, pain, etc. reﬂecting their importance. Major
advantages of such dosage form are their administration with-
out the use of water fulﬁlling the need of target population
seeking convenience in drug administration along with bypass-
ing the hepatic metabolism, consequently, leading to improved
therapeutic response.
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